IQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has received a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $243.5882.

A number of equities analysts have issued reports on IQV shares. BMO Capital Markets assumed coverage on IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Barclays set a $230.00 price target on shares of IQVIA in a research report on Monday. Finally, UBS Group raised their price objective on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th.

IQVIA Stock Down 0.9%

Shares of NYSE:IQV opened at $221.56 on Wednesday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market cap of $37.73 billion, a P/E ratio of 30.39, a P/E/G ratio of 2.51 and a beta of 1.37. IQVIA has a 12 month low of $134.65 and a 12 month high of $234.29. The company’s 50-day moving average price is $217.81 and its two-hundred day moving average price is $191.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Large investors have recently made changes to their positions in the stock. Boston Partners acquired a new position in IQVIA in the 3rd quarter worth $676,698,000. Artisan Partners Limited Partnership acquired a new position in shares of IQVIA during the second quarter worth about $515,772,000. Norges Bank bought a new position in shares of IQVIA during the second quarter worth about $270,160,000. AQR Capital Management LLC lifted its stake in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares in the last quarter. Finally, Laurel Wealth Advisors LLC boosted its position in IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.